tiprankstipranks
Trending News
More News >
Eurofins Scientific (FR:ERF)
:ERF
Advertisement

Eurofins Scientific (ERF) AI Stock Analysis

Compare
35 Followers

Top Page

FR:ERF

Eurofins Scientific

(LSE:ERF)

Select Model
Select Model
Select Model
Neutral 64 (OpenAI - 4o)
Rating:64Neutral
Price Target:
€68.00
▲(11.55% Upside)
Eurofins Scientific's strong financial performance, characterized by robust cash flow and stable profitability, is a key strength. However, technical indicators suggest weak short-term momentum, and the valuation indicates moderate pricing with a low dividend yield. These factors combine to give a balanced overall stock score.

Eurofins Scientific (ERF) vs. iShares MSCI France ETF (EWQ)

Eurofins Scientific Business Overview & Revenue Model

Company DescriptionEurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
How the Company Makes MoneyEurofins Scientific generates revenue primarily through its extensive portfolio of laboratory services, charging clients for testing and analysis across its various sectors. Key revenue streams include food testing services, which account for a significant portion of their income, as well as environmental testing and pharmaceutical research services. The company benefits from long-term contracts with clients in regulated industries, ensuring a steady flow of income. Additionally, Eurofins invests in strategic acquisitions to expand its service offerings and market reach, which further enhances its revenue potential. Partnerships with pharmaceutical companies and regulatory bodies also play a crucial role in securing contracts for testing and compliance services, driving sustained earnings growth.

Eurofins Scientific Financial Statement Overview

Summary
Eurofins Scientific shows strong financial performance with consistent revenue growth and profitability. The balance sheet is stable, though leverage has increased slightly. Robust cash flow generation supports future growth opportunities.
Income Statement
75
Positive
Eurofins Scientific exhibits strong profitability with a gross profit margin consistently above 60%. The company demonstrated a notable revenue growth rate of 6.7% in 2024, recovering from a slight decline in 2023. However, EBIT for 2024 was missing, limiting assessment in that area. Net profit margin increased to 5.8% in 2024, indicating improving efficiency.
Balance Sheet
70
Positive
The balance sheet shows a solid equity base with an equity ratio of 49.0% in 2024, reflecting financial stability. However, the debt-to-equity ratio increased slightly to 0.68, which suggests a moderate level of leverage. Return on equity improved to 7.6% in 2024, indicating efficient use of equity capital.
Cash Flow
80
Positive
Eurofins Scientific's cash flow statement reflects robust operating cash flows, with an increase to €1.32 billion in 2024. The free cash flow to net income ratio is healthy, demonstrating strong cash generation relative to net income. Free cash flow grew significantly by 68.9% in 2024, highlighting improved liquidity and potential for reinvestment.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.34B6.95B6.51B6.71B6.72B5.44B
Gross Profit756.80M4.71B620.40M4.49B4.57B3.69B
EBITDA1.09B1.38B1.22B1.36B1.71B1.28B
Net Income309.00M406.40M310.30M610.20M782.60M539.40M
Balance Sheet
Total Assets10.59B10.89B10.89B10.08B9.33B8.58B
Cash, Cash Equivalents and Short-Term Investments753.30M613.90M1.22B486.60M515.30M912.40M
Total Debt4.11B3.61B3.93B3.33B2.75B3.15B
Total Liabilities5.91B5.50B5.75B5.23B4.66B4.86B
Stockholders Equity4.64B5.34B5.08B4.78B4.65B3.69B
Cash Flow
Free Cash Flow626.00M790.50M467.80M476.10M990.30M868.00M
Operating Cash Flow972.75M1.32B1.02B1.14B1.51B1.22B
Investing Cash Flow-779.40M-846.50M-681.10M-855.90M-1.03B-525.00M
Financing Cash Flow-336.60M-1.09B495.80M-311.30M-910.30M-48.60M

Eurofins Scientific Technical Analysis

Technical Analysis Sentiment
Negative
Last Price60.96
Price Trends
50DMA
64.87
Negative
100DMA
61.86
Negative
200DMA
55.71
Positive
Market Momentum
MACD
-0.90
Positive
RSI
33.23
Neutral
STOCH
13.19
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ERF, the sentiment is Negative. The current price of 60.96 is below the 20-day moving average (MA) of 62.86, below the 50-day MA of 64.87, and above the 200-day MA of 55.71, indicating a neutral trend. The MACD of -0.90 indicates Positive momentum. The RSI at 33.23 is Neutral, neither overbought nor oversold. The STOCH value of 13.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ERF.

Eurofins Scientific Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
€9.23B20.618.27%1.25%9.57%-34.30%
70
Neutral
€13.36B35.2810.28%0.80%8.28%-8.08%
64
Neutral
€11.10B26.0211.27%0.98%6.25%18.93%
60
Neutral
€16.70B74.125.62%0.40%5.44%30.04%
58
Neutral
€253.14M108.072.24%12.75%-65.94%
55
Neutral
$13.29B17.4210.03%0.93%7.13%-12.93%
* Services Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:ERF
Eurofins Scientific
60.96
4.69
8.34%
FR:BIM
bioMerieux
113.00
6.19
5.80%
FR:IPN
Ipsen
111.60
2.57
2.36%
FR:DIM
Sartorius Stedim Biotech
171.55
-15.49
-8.28%
FR:ALERS
Eurobio-Scientific SA
25.30
-0.05
-0.20%
FR:ALECR
Eurofins-Cerep SA
18,200.00
-1,400.00
-7.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 16, 2025